Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Completed · Phase 4 · NCT06806657
Conditions: Hereditary Angioedema
At a glance
- Research payments reported, 2025
- $168,962
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- CSL Behring
- Tested
- Garadacimab (biological)
- Dates
- Started 2025-04-28; completion 2026-06-29
- Results posted
- Not yet
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
From ClinicalTrials.gov, last updated 2026-07-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $168,962 in research payments for this study in 2025 (51 payments).
Products named: Andembry
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Connie Hsu, MD Allergy & Immunology · Litchfield Park, AZ
- Donald Levy, MD Allergy & Immunology · Orange, CA
- Raffi Tachdjian, M.D. Allergy & Immunology · Santa Monica, CA
- Jonathan A. Bernstein, MD Allergy & Immunology · Cincinnati, OH
- Rafael Firszt, MD Specialist · West Valley City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $62,041
- Research Solutions of Arizona (dcrpi) $44,214
- Bernstein Clinical Research Center $40,239
- Chronicle Bio Inc $16,040
- Donald Levy $2,707
- Aire Medical of Los Angeles $2,707
- Metrodora Institute LLC $1,015
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.